Nyt fra tidsskrifterne
Søgeord (evusheld) valgt.
4 emner vises.
1
Serum neutralization of SARS‐CoV‐2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld
Qianqian Zhao, Xin Wang, Ze Zhang, Xuefei Liu, Ping Wang, Jin Cao, Qiming Liang, Jieming Qu, Min Zhou
Journal of Medical Virology, 6.07.2023
Tilføjet 6.07.2023
2
Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A systematic review and meta‐analysis
Arto Yuwono Soeroto; Theo Audi Yanto; Andree Kurniawan; Timotius Ivan Hariyanto;
Reviews in Medical Virology, 24.04.2023
Tilføjet 24.04.2023
Some proportions of populations, such as immunocompromised patients and organ transplant recipients might have inadequate immune responses to the vaccine for coronavirus disease 2019 (COVID‐19). For these groups of populations, administering monoclonal antibodies might offer some additional protection. This review sought to analyze the effectiveness and safety of tixagevimab‐cilgavimab (Evusheld) as pre‐exposure prophylaxis against COVID‐19. We used specific keywords to comprehensively search for potential studies on PubMed, Scopus, Europe PMC, and sources until 3 September 2022. We collected all published articles that analyzed tixagevimab‐cilgavimab on the course of COVID‐19. Review Manager 5.4 was utilized for statistical analysis. Six studies were included. Our pooled analysis revealed that tixagevimab‐cilgavimab prophylaxis may decrease the rate of SARS‐CoV‐2 infection (OR: 0.24; 95% CI: 0.15–0.40,
Læs mere
Tjek på PubMed
3
Updated COVID-19 Guidance for People Who Are Immunocompromised
Journal of the American Medical Association, 1.03.2023
Tilføjet 1.03.2023
In late January, the US Food and Drug Administration announced that Evusheld (the combined monoclonal antibodies tixagevimab and cilgavimab) is not currently authorized for emergency use because it’s likely ineffective against more than 90% of SARS-CoV-2 variants now circulating in the US. Evusheld had been used as COVID-19 preexposure prophylaxis among certain patients who are immunocompromised.
Læs mere
Tjek på PubMed
4
DISCRIMINATING ENDOGENOUS VACCINE‐ELICITED ANTI‐SPIKE ANTIBODY RESPONSES FROM EXOGENOUS ANTI‐SPIKE MONOCLONAL ANTIBODIES: THE CASE OF EVUSHELD
Daniele Focosi, Fabrizio Maggi, Shmuel Shoham, Arturo Casadevall
Journal of Medical Virology, 4.11.2022
Tilføjet 5.11.2022